• Merbromin as a Mixed-Type Inhibitor of SARS-CoV-2 3CLpro Pro

  2026-04-21

  This study identifies Merbromin as a selective, mixed-type inhibitor of the SARS-CoV-2 main protease (3CLpro), a key enzyme in viral replication. High-throughput enzymatic screening and kinetic analyses provide insights into Merbromin's mechanism, supporting its potential as a scaffold for antiviral drug development.

• Superoxide Dismutase (SOD) Activity Assay Kit: Technical Gui

  2026-04-20

  The Superoxide Dismutase (SOD) Activity Assay Kit enables quantitative detection of SOD enzyme activity in biological samples using a fast, colorimetric workflow. It is well-suited for oxidative stress, antioxidative enzyme, and reactive oxygen species measurement protocols where robust, reproducible SOD quantification is required. The kit is not intended for diagnostic or clinical applications, and results should be interpreted within the constraints of colorimetric endpoint assays.

• Ceftolozane Sulfate: Optimizing Workflows for Resistant Path

  2026-04-20

  Ceftolozane sulfate enables precise in vitro and in vivo modeling of antibacterial resistance, especially for Pseudomonas aeruginosa. This article provides actionable protocols and troubleshooting guidance for maximizing experimental reliability and translating bench data into clinically relevant insights.

• Enhancing mRNA Loading in Kidney-Targeted Nanoparticles: Exc

  2026-04-19

  This study investigates how different excipients impact the mRNA loading capacity of polymeric mesoscale nanoparticles (MNPs) designed for kidney-targeted delivery. By systematically evaluating excipient-mRNA interactions and resultant nanoparticle characteristics, the work advances nanoparticle formulation strategies for renal gene therapy and functional mRNA delivery.

• CypD-Dependent mPTP Opening Drives mtDNA Release in Ferropto

  2026-04-18

  This study uncovers the pivotal role of Cyclophilin D (CypD)-mediated mitochondrial permeability transition pore (mPTP) opening in facilitating the release of oxidized mitochondrial DNA during ferroptosis. These released mtDNAs activate the cGAS-STING pathway, advancing our understanding of how mitochondrial signaling integrates into regulated cell death and highlighting new directions for cancer therapy.

• ABT-737: Precision Targeting of BCL-2 in Hematologic Maligna

  2026-04-17

  Explore how ABT-737, a potent BCL-2 protein inhibitor, enables precision apoptosis induction in hematologic cancers. This article uniquely dissects its selective mechanism and translational assay guidance for advanced oncology research.

• DiscoveryProbe FDA-approved Drug Library: Transforming High-

  2026-04-16

  Unleash the full translational power of the DiscoveryProbe FDA-approved Drug Library for drug repositioning and pharmacological target identification. This guide delivers actionable workflows, troubleshooting strategies, and real-world use-cases—bridging high-content screening innovation and robust assay reproducibility.

• Hypoxia Pathway Modulation Restricts MeV and NiV: Mechanisti

  2026-04-15

  This study demonstrates that pharmacological activation of the hypoxia response pathway, specifically via PHD inhibition, robustly restricts measles and Nipah virus infections in vitro and ex vivo. These findings highlight the therapeutic potential of targeting host metabolic regulators to combat emerging viral pathogens.

• A40926: Dalbavancin Precursor for Advanced Antibacterial Ass

  2026-04-14

  A40926 sets a new benchmark for in vitro antibacterial assays targeting Gram-positive and multidrug-resistant pathogens, including MRSA and Neisseria gonorrhoeae. Its potent cell wall inhibition, low MIC values, and robust fermentation yields enable translational research into next-generation antibiotics.

• Dissecting In Vitro Drug Response: Insights from Fractional

  2026-04-13

  Schwartz's dissertation advances the evaluation of anti-cancer agents by rigorously distinguishing between proliferative arrest and cell death in in vitro assays. This nuanced approach clarifies mechanisms of drug action and supports more precise preclinical decision-making.

• Captopril in Experimental Pharmacology: Mechanistic Precisio

  2026-04-13

  Explore how Captopril, a potent ACE inhibitor, enables mechanistically precise hypertension and oncology assays. This article uniquely bridges bradykinin receptor research and protocol optimization, providing actionable insights beyond standard workflows.

• Fosinopril Sodium: Strategic Leverage in Translational CV Re

  2026-04-12

  This thought-leadership article explores how Fosinopril sodium, a third-generation phosphinic acid ACE inhibitor, is redefining translational cardiovascular and hypertension research. Focusing on mechanistic depth, strategic guidance, and validated protocols, we analyze its competitive advantages, real-world applications, and outlook for advancing precision in blood pressure and renal hemodynamics modulation. The discussion integrates clinical trial learnings, best practices, and the expanding framework built by APExBIO’s high-purity offering.

• Bestatin Hydrochloride Modulates Angiotensin-Evoked Neuronal

  2026-04-12

  Harding and Felix (1987) demonstrated that bestatin hydrochloride, an aminopeptidase B inhibitor, significantly enhances the neuronal response to angiotensin II and III in the rat brain, supporting an obligatory conversion of angiotensin II to angiotensin III for physiological activity. This finding informs the mechanistic understanding of neuropeptidergic signaling and the broader application of aminopeptidase inhibition in neuroscience and cancer research.

• Anlotinib Hydrochloride: Multi-Target TKI for Angiogenesis A

  2026-04-11

  Anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, offers robust, nanomolar-level inhibition of key angiogenic pathways, outperforming traditional TKIs in functional endothelial assays. Its high selectivity, minimal cytotoxicity, and versatility make it a gold-standard tool for next-generation cancer and vascular research workflows.

• Latrunculin A: Reversible Inhibitor of Actin Assembly in Cel

  2026-04-11

  Latrunculin A empowers researchers with precise, rapid, and reversible actin cytoskeleton disruption, enabling advanced studies of cell morphology, motility, and host-pathogen interactions. Leveraging cutting-edge proteomic insights, this guide details best practices, troubleshooting, and cross-disciplinary applications for Latrunculin A in both classical and emerging experimental workflows.

11524 records 1/769 page Next 12345 下5页 Last page